Astragaloside III
Based on 2 publication(s) in Google Scholar
Astragaloside III is a triterpenoid saponin. Astragaloside III can be extracted from Astragalus root. Astragaloside III increases NKG2D and induces TACE phosphorylation. Astragaloside III induces Apoptosis. Astragaloside III has antiviral activity against dengue serotypes 1 and 3. Astragaloside III has anticancer activity against breast and colon cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.70%
- CAS No.: 84687-42-3
- Formule: C41H68O14
- Masse moléculaire:784.97
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Glycoside Compound Library
HY-L042
-
Medicine Food Homology Compound Library
HY-L055
-
Terpenoids Library
HY-L056
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Anti-Cancer Natural Product Library
HY-L107
-
Antiviral Traditional Chinese Medicine Active Compound Library
HY-L113
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Heterocyclic Compound Library
HY-L138
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Bioactive Compound Library
HY-L001
-
Tibetan Medicine Compound Library
HY-L191
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Pattern Recognition Receptors Library
HY-L237
-
Mongolian Medicine Compound Library
HY-L238
-
Natural Product Diversity Scaffold Library
HY-L245
-
Tonifying Traditional Chinese Medicine Monomer Compound Library
HY-L246
-
Mass Spectrometry Natural Product Library
HY-L262
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
Publications Citing Use of MedChemExpress (MCE) Astragaloside III
More
Activité biologique
Astragaloside III (3.125-6.25 μg/mL) shows antiviral activity against dengue serotype 1 and serotype 3[1].
Astragaloside III (4-40 nM) can significantly increase the expression of NKG2D and the production of IFN-γ in NK cells[2].
Astragaloside III (10 μM; 8 h) significantly reduces the cell viability of bEnd.3 cells (about 10%)[3].
Astragaloside III (10-100 ng/mL; 24-48 h) reduces the viability of MCF-7 breast cancer cells and increase the apoptosis rate[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Mouse brain microvascular endothelial bEnd.3 cells
-
Concentration:1000 nM
-
Incubation Time:5 min, 15 min, 30 min, 60 min, 120 min
-
Result:Induced phosphorylation of TACE.
Astragaloside III (10-20 mg/kg; i.p.; every 2 days) can inhibit the growth of MDA-MB-231 breast cancer xenografts in nude mice and increase tumor cell apoptosis[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c mice (6-8 weeks old) with CT26 colon cancer xenografts[2]
-
Dosage:50 mg/kg (mixed with 10% PEG-200 and 10% ethanol)
-
Administration:Intravenous injection, once every 2 days, for 5 times
-
Result:Significantly reduced tumor weight and volume.
Decreased the fold change of tumor volume increase, prolonged the survival rate (30% survival by day 50 vs. all dead in control by day 40).
Increased NK cell infiltration in tumors, and upregulated NKG2D, IFN-γ, and Fas expression in NK cells without obvious organ toxicity.
Chemical Information
-
CAS No. 84687-42-3
-
Appearance Solid
-
Masse moléculaire 784.97
-
Formule C41H68O14
-
Color White to off-white
-
SMILES
O[C@@H]1[C@@H](O)[C@]([H])(O[C@@H]2[C@@H](O)[C@H](O)CO[C@]2(O[C@@H]3C(C)(C)[C@@]([C@@H](O)C[C@]4([H])[C@@]56CC[C@@]7(C)[C@@]4(C)C[C@H](O)[C@@]7([C@]8(C)O[C@H](C(C)(O)C)CC8)[H])([H])[C@]5(C6)CC3)[H])O[C@H](CO)[C@H]1O
-
Structure Classification
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Phytother Res
Astragaloside III activates TACE/ADAM17-dependent anti-inflammatory and growth factor signaling in endothelial cells in a p38-dependent fashion. [Abstract]2020 May;34(5):1096-1107. PMID: 32197276 -
Exp Cell Res
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]2020 Aug 1;393(1):112054. PMID: 32376287
Solvant et solubilité
DMSO : 50 mg/mL (63.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (3.18 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (286 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Indu P, et al. Antiviral activity of astragaloside II, astragaloside III and astragaloside IV compounds against dengue virus: Computational docking and in vitro studies. Microb Pathog. 2021 Mar;152:104563. [Content Brief]
[2]. Chen X, et al. Astragaloside III Enhances Anti-Tumor Response of NK Cells by Elevating NKG2D and IFN-γ. Front Pharmacol. 2019 Aug 13;10:898. [Content Brief]
[3]. Wang H, et al. Astragaloside III activates TACE/ADAM17-dependent anti-inflammatory and growth factor signaling in endothelial cells in a p38-dependent fashion. Phytother Res. 2020 May;34(5):1096-1107. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2739 mL | 6.3697 mL | 12.7393 mL | 31.8484 mL |
| 5 mM | 0.2548 mL | 1.2739 mL | 2.5479 mL | 6.3697 mL | |
| 10 mM | 0.1274 mL | 0.6370 mL | 1.2739 mL | 3.1848 mL | |
| 15 mM | 0.0849 mL | 0.4246 mL | 0.8493 mL | 2.1232 mL | |
| 20 mM | 0.0637 mL | 0.3185 mL | 0.6370 mL | 1.5924 mL | |
| 25 mM | 0.0510 mL | 0.2548 mL | 0.5096 mL | 1.2739 mL | |
| 30 mM | 0.0425 mL | 0.2123 mL | 0.4246 mL | 1.0616 mL | |
| 40 mM | 0.0318 mL | 0.1592 mL | 0.3185 mL | 0.7962 mL | |
| 50 mM | 0.0255 mL | 0.1274 mL | 0.2548 mL | 0.6370 mL | |
| 60 mM | 0.0212 mL | 0.1062 mL | 0.2123 mL | 0.5308 mL |
Astragaloside III Related Classifications
HY-N0434 Related Classifications
Powered by Bioz